|20th October 2020||Curet Myriam||875||Exercise of derivative||$238.91||$209,049.14|
|20th October 2020||Curet Myriam||875||Open or private sale||$736.12||$644,105.00|
|14th October 2020||Jeffrey Robert Ajer||2,121||Open or private sale||$79.91||$169,489.11|
|28th September 2020||Jeffrey Robert Ajer||3,250||Open or private sale||$17.25||$56,062.50|
|25th September 2020||Robert Chess||5,500||Open or private sale||$17.75||$97,625.00|
|22nd September 2020||Roy A Whitfield||9,100||Grant/award etc.||$0.00|
|22nd September 2020||R Scott Greer||9,100||Grant/award etc.||$0.00|
|22nd September 2020||Jeffrey Robert Ajer||9,100||Grant/award etc.||$0.00|
|22nd September 2020||Curet Myriam||9,100||Grant/award etc.||$0.00|
|22nd September 2020||Robert Chess||9,100||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Nektar Therapeutics is a biopharmaceutical company. It focuses on the therapies for cancer, autoimmune disease, and chronic pain. The company was founded in 1990 and is headquartered in San Francisco, CA.